(Total Views: 544)
Posted On: 03/14/2022 1:04:32 AM
Post# of 36564
Feurstein: “ Regular insulin is slow acting and isn't used by diabetics around mealtime, which makes the Oral-lyn data irrelevant.”
Btw, a bit dated, but once he said that he immediately was wrong. Oral-Lyn is and was compared to meal time insulin. Always. And they’re supposedly fast acting. He didn’t understand what he was reading scientifically. And as Dr. Anderson told me last month, under CEO Fletcher they fixed the formulation to just a couple sprays. And Dr. Anderson was unhappy that Joe didn’t move that forward. So he resigned in dissatisfaction with the company. That’s a big loss, as Dr. Anderson was the LLY executive working with Gluskin. Any new Generex needs more Dr. Anderson and less nonsense acquisitions that have nothing to do with science as we had under Joe. At least, according to Dr. Andy.
Btw, a bit dated, but once he said that he immediately was wrong. Oral-Lyn is and was compared to meal time insulin. Always. And they’re supposedly fast acting. He didn’t understand what he was reading scientifically. And as Dr. Anderson told me last month, under CEO Fletcher they fixed the formulation to just a couple sprays. And Dr. Anderson was unhappy that Joe didn’t move that forward. So he resigned in dissatisfaction with the company. That’s a big loss, as Dr. Anderson was the LLY executive working with Gluskin. Any new Generex needs more Dr. Anderson and less nonsense acquisitions that have nothing to do with science as we had under Joe. At least, according to Dr. Andy.
(2)
(0)
